The U.S. Food and Drug Administration expanded the approved use of Novartis’ radioligand therapy Pluvicto to treat PSMA-positive metastatic hormone-sensitive prostate cancer.
This expansion allows the drug to be used at an earlier stage of the disease. Moving the treatment window forward potentially establishes a new standard of care for patients facing metastatic prostate cancer before it reaches later stages.
Pluvicto is designed for patients with PSMA-positive disease. The FDA's decision to include metastatic hormone-sensitive prostate cancer (mHSPC) in the approved indication means the therapy can now be administered to a broader demographic of patients.
According to industry reports, this expanded indication nearly doubles the eligible patient population for the therapy [1]. By targeting the disease earlier in its progression, Novartis aims to improve outcomes for a larger group of individuals who previously had to wait for later stages of cancer to qualify for the treatment.
From a business perspective, the move increases the commercial potential of the drug. Novartis said it has set a peak sales target of $5 billion for Pluvicto [1].
The radioligand therapy works by delivering radiation directly to cells expressing the prostate-specific membrane antigen (PSMA). This targeted approach is intended to minimize damage to healthy tissue, while maximizing the impact on cancer cells. The expansion into the hormone-sensitive phase of the disease represents a strategic shift in how these therapies are deployed in clinical settings.
“The expanded indication nearly doubles the eligible patient population for Pluvicto.”
This regulatory expansion shifts Pluvicto from a late-stage rescue therapy to an earlier intervention. By targeting the hormone-sensitive phase of metastatic prostate cancer, the treatment may slow disease progression more effectively than waiting for hormone-resistant stages, while simultaneously expanding the market reach for Novartis' radioligand portfolio.
